bioRxiv Science⌕ Search

Biology subjects

Kurtz, P.

Publications and source records attributed to Kurtz, P..

2 recordsLinked to original sources

lydemapr: an R package to track the spread of the invasive Spotted Lanternfly (Lycorma delicatula, White 1845) (Hemiptera, Fulgoridae) in the United States

A crucial asset in the management of invasive species is the open-access sharing of data on the range of invaders and the progression of their spread. Such data should be current, comprehensive, consistent, and standardized, to support reproducible and comparable forecasting efforts among multiple researchers and managers. Here, we present the lydemapr R package containing spatiotemporal data and mapping functions to visualize the current spread of the spotted lanternfly (Lycorma delicatula, White 1841) in the Western Hemisphere. The spotted lanternfly is a forest and agricultural pest in the eastern Mid-Atlantic region of the U.S., where it was first discovered in 2014. As of 2022, it has been found in 12 states according to state and federal departments of agriculture. However, the lack of easily accessible, fine-scale data on its spread hampers research and management efforts. We obtained multiple memoranda-of-understanding from several agencies and citizen-science projects, gaining access to their internal data on spotted lanternfly point observations. We then cleaned, harmonized, anonymized, and combined the individual data sources into a single comprehensive dataset. The resulting dataset contains spatial data gridded at the 1 km2 resolution, with yearly information on the presence/absence of spotted lanternflies, establishment status, and population density across 658,392 observations. The lydemapr package will aid researchers, managers, and the public in their understanding, modeling, and managing of the spread of this invasive pest.

ecology↗

The neuropeptides VIP and PACAP inhibit SARS-CoV-2 replication in monocytes and lung epithelial cells and decrease the production of proinflammatory cytokines in infected cells.

Infection by SARS-CoV-2 may elicit uncontrolled and damaging inflammatory responses. Thus, it is critical to identify compounds able to inhibit virus replication and thwart the inflammatory reaction. Here, we show that the plasma levels of the immunoregulatory neuropeptide VIP are elevated in patients with severe COVID-19, correlating with reduced inflammatory mediators and with survival on those patients. In vitro, VIP and PACAP, highly similar neuropeptides, decreased the SARS-CoV-2 genome replication in human monocytes and viral production in lung epithelial cells, also reducing cell death. Both neuropeptides inhibited the production of proinflammatory mediators in lung epithelial cells and in monocytes. VIP and PACAP prevented in monocytes the SARS-CoV-2-induced activation of NF-kB and SREBP1 and SREBP2, transcriptions factors involved in proinflammatory reactions and lipid metabolism, respectively. They also promoted CREB activation, a transcription factor with antiapoptotic activity and negative regulator of NF-kB. Specific inhibition of NF-kB and SREBP1/2 reproduced the anti-inflammatory, antiviral and cell death protection effects of VIP and PACAP. Our results support further clinical investigations of these neuropeptides against COVID-19.

microbiology↗